Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0235950
Disease: Zinc deficiency
Zinc deficiency 		0.010 Biomarker disease BEFREE Zinc deficiency increases the susceptibility of human neuroblastoma cells to lead-induced activator protein-1 activation. 16484283 2006
CUI: C0042769
Disease: Virus Diseases
Virus Diseases 		0.030 AlteredExpression group BEFREE C-Jun N-terminal kinases (JNK) are activated in course of many viral infections. 22628315 2012
CUI: C0042769
Disease: Virus Diseases
Virus Diseases 		0.030 Biomarker group BEFREE Among the AP-1 factors identified to bind to their cognate DNA element during viral infections of Madin-Darby canine kidney and U937 cells are those that are regulated via phosphorylation by JNKs. 11150300 2001
CUI: C0042769
Disease: Virus Diseases
Virus Diseases 		0.030 AlteredExpression group BEFREE Activation of AP-1 genes was also observed to occur during infections with other enteroviruses and with Semliki Forest A7(74) virus, suggesting that the phosphorylation of MAPKs and induction of AP-1 gene expression may be important regulators of host cell behavior during viral infections. 9770423 1998
CUI: C0947751
Disease: Vascular inflammations
Vascular inflammations 		0.010 AlteredExpression phenotype BEFREE AhR mediates indoxyl sulfate-enhanced leukocyte-endothelial interactions through AP-1 transcriptional activity, which may constitute a new mechanism of vascular inflammation in patients with renal disease. 26860885 2016
CUI: C0042373
Disease: Vascular Diseases
Vascular Diseases 		0.020 Biomarker group BEFREE Transcription factor activator protein-1 (AP-1) is activated and upregulated in injured arterial smooth muscle cells in vivo, yet the exact role of the AP-1--related pathway in vascular disease in vivo has remained unclear. 11889018 2002
CUI: C0042373
Disease: Vascular Diseases
Vascular Diseases 		0.020 Biomarker group BEFREE Our findings demonstrate the feasibility, efficacy, and specificity of the anti-AP-1 RNA dON approach for the treatment of allograft vasculopathy in an animal model. 31720303 2019
CUI: C0042345
Disease: Varicosity
Varicosity 		0.010 AlteredExpression disease BEFREE In this context, we recently reported that a chronic increase in venous wall stress or biomechanical stretch is sufficient to cause development of varicose veins through the activation of the transcription factor activator protein 1. 26908399 2016
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.060 Biomarker phenotype BEFREE Although the c-jun oncogene is an integral part of the AP-1 transcriptional complex implicated in the process of tumor promotion, its role in the pathogenesis of human tumors is unknown. 8542585 1996
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.060 Biomarker phenotype BEFREE Inhibitors of AP-1 have been shown to block tumor promotion, transformation, progression and invasion. 16784822 2006
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.060 Biomarker phenotype BEFREE We conclude that transactivation of a subset of AP-1-dependent genes is required for tumor promotion and may be targeted for cancer prevention. 10449779 1999
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.060 Biomarker phenotype BEFREE The net outcome of SAG-mediated inhibition of c-Jun/AP-1 (pro-tumor promotion) and of p27 (antiproliferation) increased skin hyperplasia, with no apparent effect on apoptosis, as evidenced by increased skin thickness, and increased rate of DNA synthesis, but hardly any apoptosis. 18258608 2008
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.060 AlteredExpression phenotype BEFREE Activation of activator protein 1 (AP-1) and nuclear factor kappaB (NFkappaB)-dependent transcription is required for tumor promotion in cell culture models and transgenic mice. 17363560 2007
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.060 Biomarker phenotype BEFREE Overall, these results indicate that MnSOD regulates both cellular redox status and selectively modulates PKCepsilon signaling, thereby delaying AP-1 activation and inhibiting tumor promotion, resulting in reduction of tumors in MnSOD transgenic mice. 11507057 2001
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 AlteredExpression phenotype BEFREE The actin-binding protein Ezrin and the activator protein 1 (AP-1) transcription factor are implicated in cancer progression and metastasis. 23752190 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 AlteredExpression phenotype BEFREE Here we show that at the receiving end of the miR-10b pathway is the proto-oncogene c-Jun, a transcription factor that plays a critical role in stimulation of cell proliferation and tumor progression. c-Jun is known to be translationally activated by loss of cell contacts or restructuring of the cytoskeleton. 27494896 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 AlteredExpression phenotype BEFREE Gefitinib-resistant cells acquired an increased expression and activation of JUN, a known oncogene involved in cancer progression. 28566434 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 AlteredExpression phenotype BEFREE In summary, there are a variety of mechanisms underlying the induction of c-Jun protein expression and activity leading to tumor progression and development, and this diverse regulatory machinery is due to the heterogeneity of different tumor types, particularly in malignant melanoma. 24315690 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 Biomarker phenotype BEFREE Nuclear factor-kappaB (NF-κB) and activator protein 1 (AP-1) is a major transcription factor which regulates many biological and pathological processes such as inflammation and cell proliferation, which are major implicates in cancer progression. 29287195 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 Biomarker phenotype BEFREE Our results show that Jun proteins (pc-Jun and JunD) influence carcinogenesis and tumour progression, suggesting a significant role as prognostic predictors in human ovarian carcinoma. 23942796 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.070 AlteredExpression phenotype BEFREE The AP-1 factor JUNB was shown to drive ALCL proliferation and the expression of the characteristic ALCL Ki-1 antigen, CD30. cJUN and JUNB target PDGFRB, thereby leading to tumor progression and dissemination. 25961698 2015
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.010 AlteredExpression phenotype BEFREE Furthermore, we expose how the misdirected action of the main regulators of these miRNAs, such as nuclear factor κB (NF-κB), activator protein-1 (AP-1), and signal transduction and activators of transcription (STAT) transcription factors, or AKT and transforming growth factor β (TGFβ) signaling pathways, can contribute to decrease anti-tumor immunity and enhance cell proliferation and oncogenesis. 23550646 2013
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 GeneticVariation phenotype BEFREE Following direct co-culture with MSCs, breast cancer cells expressed elevated levels of oncogenes (NCOA4, FOS), proto-oncogenes (FYN, JUN), genes associated with invasion (MMP11), angiogenesis (VEGF) and anti-apoptosis (IGF1R, BCL2). 20087650 2010
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 Biomarker phenotype BEFREE Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. 22132731 2011
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 AlteredExpression phenotype BEFREE In summary, these results suggest that c-Src, mitogen-activated protein kinase, and a composite activator protein 1 on the uPA promoter are responsible for EGF-induced uPA expression and GBM invasion. 20467333 2010